Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
20.35
-0.90 (-4.24%)
Feb 4, 2026, 2:30 PM EST - Market open
Syndax Pharmaceuticals Employees
Syndax Pharmaceuticals had 270 employees as of December 31, 2024. The number of employees increased by 86 or 46.74% compared to the previous year.
Employees
270
Change (1Y)
86
Growth (1Y)
46.74%
Revenue / Employee
$412,237
Profits / Employee
-$1,153,989
Market Cap
1.77B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 270 | 86 | 46.74% | 270 | 0 |
| Dec 31, 2023 | 184 | 77 | 71.96% | 184 | 0 |
| Dec 31, 2022 | 107 | 48 | 81.36% | 107 | 0 |
| Dec 31, 2021 | 59 | 16 | 37.21% | 59 | 0 |
| Dec 31, 2020 | 43 | 8 | 22.86% | 43 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,869 |
| MannKind | 407 |
| Ardelyx | 395 |
| Vericel | 357 |
| Nuvation Bio | 291 |
| Nurix Therapeutics | 286 |
| Stoke Therapeutics | 128 |
| Pharvaris | 118 |
SNDX News
- 22 days ago - Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 23 days ago - Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S. - GlobeNewsWire
- 4 weeks ago - Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Syndax Pharma: Continuing Execution In AML - Seeking Alpha
- 7 weeks ago - Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025 - GlobeNewsWire
- 2 months ago - Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting Transcript - Seeking Alpha
- 2 months ago - Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum - GlobeNewsWire